Figure 2

A) Enrichment analysis of screened active compounds by therapeutic category. B) Drug activity profile across different cell lines and primary cell culture of 21 active drugs in H295R cells. Black box indicates active compound, grey box indicates compound with inconclusive activity, white box represents inactive compounds, and the compounds that were not tested are labeled in stripe. The criteria for compound activity are described in Data Analysis section. TPC-1: papillary thyroid cancer cell line, NF-kB: ME-180 human cervical carcinoma cell line, MRC5: normal human fetal lung fibroblasts, Mesangial: human kidney glomerular mesangial cell line, LAM: lymphoangioleiomyosis cell line (LAM, a rare lung disease that results in a proliferation of disorderly smooth muscle growth). C) Dose–response curve of NCI-H295R treated with cisplatinum, etoposide and mitotane.